| Size | Price | Stock | Qty |
|---|---|---|---|
| 5g |
|
||
| 10g |
|
||
| 25g |
|
||
| 50g |
|
||
| Other Sizes |
|
Purity: ≥98%
Naproxen Sodium (formerly RS 3650; RS-3650; Naproxen natrium), an approved non-steroidal anti-inflammatory drug (NSAID), is a nonselective COX inhibitor for COX-1 and COX-2 with potential anti-inflammatory activity. It inhibits COX-1 and COX-2 with IC50s of 8.7 μM and 5.2 μM, respectively.
| ln Vitro |
When absorbed, naproxen etemesil, a lipophilic, non-acidic, inactive prodrug, hydrolyzes to produce naproxen, which is pharmacologically active. One well-known nonsteroidal anti-inflammatory medication is naproxen. In intact cells, naproxen inhibits COX-1 and COX-2 approximately equipotently, with IC50 values of 2.2 μg/mL and 1.3 μg/mL, respectively[1].
|
||
|---|---|---|---|
| ln Vivo |
Naproxen reduces inflammation and inhibits fibrosis in a mouse model of lung fibrosis caused by bleomycin. Moreover, naproxen inhibits the production of the Smad3/4 complex and TGF-β levels[2]. It has been demonstrated that naproxen inhibits PGE2, pain, and fever time courses with potencies comparable to these (IC50=27, 40, and 13 μM)[3].
|
||
| Animal Protocol |
|
||
| References |
|
||
| Additional Infomation |
Naproxen sodium is an organic sodium salt consisting of equimolar amounts of naproxen(1-) anions and sodium anions. It has a role as a non-narcotic analgesic, a cyclooxygenase 2 inhibitor, a cyclooxygenase 1 inhibitor, an antipyretic and a non-steroidal anti-inflammatory drug. It contains a naproxen(1-).
Naproxen Sodium is the sodium salt form of naproxen, a member of the arylacetic acid group of non-steroidal anti-inflammatory drugs (NSAIDs) with anti-inflammatory analgesic and antipyretic properties. Naproxen sodium reversibly and competitively inhibits cyclooxygenases (COX), thereby blocking the conversion of arachidonic acid to pro-inflammatory prostaglandins. This inhibits the formation of prostaglandins that are involved in pain, inflammation and fever. An anti-inflammatory agent with analgesic and antipyretic properties. Both the acid and its sodium salt are used in the treatment of rheumatoid arthritis and other rheumatic or musculoskeletal disorders, dysmenorrhea, and acute gout. See also: Naproxen (has active moiety); Diphenhydramine hydrochloride; naproxen sodium (component of); Naproxen sodium; pseudoephedrine hydrochloride (component of) ... View More ... |
| Molecular Formula |
C14H13NAO3
|
|
|---|---|---|
| Molecular Weight |
252.24
|
|
| Exact Mass |
252.076
|
|
| CAS # |
26159-34-2
|
|
| Related CAS # |
(±)-Naproxen;23981-80-8;Naproxen;22204-53-1;Naproxen etemesil;385800-16-8
|
|
| PubChem CID |
23681059
|
|
| Appearance |
White to off-white solid powder
|
|
| Boiling Point |
403.9ºC at 760 mmHg
|
|
| Melting Point |
250-251ºC
|
|
| Flash Point |
154.5ºC
|
|
| Vapour Pressure |
3.01E-07mmHg at 25°C
|
|
| LogP |
1.701
|
|
| Hydrogen Bond Donor Count |
0
|
|
| Hydrogen Bond Acceptor Count |
3
|
|
| Rotatable Bond Count |
3
|
|
| Heavy Atom Count |
18
|
|
| Complexity |
282
|
|
| Defined Atom Stereocenter Count |
1
|
|
| SMILES |
C[C@@H](C1=CC2=C(C=C1)C=C(C=C2)OC)C(=O)[O-].[Na+]
|
|
| InChi Key |
CDBRNDSHEYLDJV-FVGYRXGTSA-M
|
|
| InChi Code |
InChI=1S/C14H14O3.Na/c1-9(14(15)16)10-3-4-12-8-13(17-2)6-5-11(12)7-10;/h3-9H,1-2H3,(H,15,16);/q;+1/p-1/t9-;/m0./s1
|
|
| Chemical Name |
2-Naphthaleneacetic acid, 6-methoxy-alpha-methyl-, sodium salt, (S)-
|
|
| Synonyms |
|
|
| HS Tariff Code |
2934.99.9001
|
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
|
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
|
|||
|---|---|---|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 0.5 mg/mL (1.98 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 5.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 0.5 mg/mL (1.98 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 5.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 0.5 mg/mL (1.98 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 120 mg/mL (475.74 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.9645 mL | 19.8224 mL | 39.6448 mL | |
| 5 mM | 0.7929 mL | 3.9645 mL | 7.9290 mL | |
| 10 mM | 0.3964 mL | 1.9822 mL | 3.9645 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT04449471 | Unknown † | Drug: Naproxen tablet | Pharmacogenetics | University of Washington | January 12, 2016 | Phase 4 |
| NCT05844995 | Completed | Drug: Acetaminophen/Naproxen Sodium | Orthodontic Pain | Johnson & Johnson Consumer Inc. (J&JCI) | September 13, 2023 | Phase 1 |
| NCT05845008 | Withdrawn | Drug: Acetaminophen/Naproxen Sodium Fixed Combination |
Orthodontic Pain | Johnson & Johnson Consumer Inc. (J&JCI) | January 15, 2024 | Phase 3 |
| NCT05982392 | Completed | Drug: Tramadol Drug: Naproxen Sodium Drug: Placebo |
Symptomatic Irreversible Pulpitis Post Operative Pain |
Dow University of Health Sciences | March 1, 2023 | Phase 2 Phase 3 |
| NCT03697889 | Completed | Drug: Naproxen sodium (test product) Drug: Naproxen sodium (reference product) |
Healthy | McNeil AB | December 3, 2018 | Phase 1 |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA